How does additional diagnostic testing influence the initial diagnosis in patients with cognitive complaints in a memory clinic setting?

Age and Ageing

Volumn 44, Issue 1, 2015, Pages 72-77

  Meijs, Anouk P ^a   Claassen, Jurgen A H R ^a,b   Olde Rikkert, Marcel G M ^a,b   Schalk, Biancaw M ^a   Meulenbroek, Olga ^a   Kessels, Roy P C ^a   Melis, René J F ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Dementia; Diagnostic accuracy; Memory clinic; MRI; Neuropsychological testing; Older people

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOLOGIC TEST; AGE; AGING; CEREBROSPINAL FLUID; COGNITION DISORDERS; FACTUAL DATABASE; MEMORY; OUTPATIENT DEPARTMENT; PREDICTIVE VALUE; PSYCHOLOGY; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COGNITION; COGNITION DISORDERS; DATABASES, FACTUAL; DEMENTIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; OUTPATIENT CLINICS, HOSPITAL; PREDICTIVE VALUE OF TESTS;

EID: 84925337701     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afu053     Document Type: Article

References (23)

1. Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 2006; 21: 17-28.
2. Román GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60.
3. Hentschel F, Kreis M, Damian M, Krumm B, Frölich L. The clinical utility of structural neuroimaging with MRI for diagnosis and differential diagnosis of dementia: a memory clinic study. Int J Geriatr Psychiatry 2005; 20: 645-50.
4. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007; 80(Spec no 2): S71-7.
5. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373-9.
6. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52: 1555-62.
7. Sjögren M, Andreasen N, Blennow K. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta 2003; 332: 1-10.
8. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2010; 31: 1867-76.
9. Schmand B, Eikelenboom P, van Gool WA. Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. J Am Geriatr Soc 2011; 59: 1705-10.
10. Geroldi C, Canu E, Bruni AC et al. The added value of neuropsychologic tests and structural imaging for the etiologic diagnosis of dementia in Italian expert centers. Alzheimer Dis Assoc Disord 2008; 22: 309-20.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
12. Verhey FR, Houx P, Van Lang N et al. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID). Int J Geriatr Psychiatry 2004; 19: 41-50.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
14. D'Ath P, Katona P, Mullan E, Evans S, Katona C. Screening, detection and management of depression in elderly primary care attenders. I: the acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract 1994; 11: 260-6.
15. Schoenberg MR, Dawson KA, Duff K, Patton D, Scott JG, Adams RL. Test performance and classification statistics for the Rey Auditory Verbal Learning Test in selected clinical samples. Arch Clin Neuropsychol 2006; 21: 693-703.
16. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 2004; 19: 203-14.
17. Conway AR, Kane MJ, Bunting MF, Hambrick DZ, Wilhelm OEngle RW. Working memory span tasks: a methodological review and user's guide. Psychon Bull Rev 2005; 12: 769-86.
18. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 655-60.
19. Oden N, van Veldhuisen PC, Scott IU, Ip MS. SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means. Drug Inf J 2010; 44: 405-20.
20. Chui H, Zhang Q. Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 1997; 49: 925-35.
21. Borghesani PR, DeMers SM, Manchanda V, Pruthi S, Lewis DHBorson S. Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. J Am Geriatr Soc 2010; 58: 1453-8.
22. Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011; 7: 486-9.
23. Moons KG, van der Graaf Y. Evaluation of added value of diagnostic tests. Ned Tijdschr Geneeskd 2000; 144: 1256-61.